Quarterly report pursuant to Section 13 or 15(d)

Sponsored Research and License Agreements (Details)

v3.20.2
Sponsored Research and License Agreements (Details)
1 Months Ended 3 Months Ended 9 Months Ended
Feb. 29, 2020
USD ($)
Jan. 31, 2020
USD ($)
Oct. 31, 2019
USD ($)
agreement
Jan. 31, 2019
USD ($)
Oct. 31, 2018
USD ($)
Sep. 30, 2020
USD ($)
Sep. 30, 2020
USD ($)
Dec. 31, 2019
USD ($)
Collaborations                
Contingent payments             $ 607,200,000  
Accounts receivable           $ 14,631,000 14,631,000 $ 10,111,000
Specified Development Events                
Collaborations                
Contingent payments             67,500,000  
Specified Regulatory Events                
Collaborations                
Contingent payments             163,700,000  
Specified Product Launch Events                
Collaborations                
Contingent payments             376,000,000.0  
Grifols                
Collaborations                
Upfront payment received       $ 30,000,000.0        
Contingent payments             277,500,000  
Deferred revenue related to upfront payment           1,800,000 1,800,000  
Revenue, cumulative catch-up   $ 25,000,000.0            
Revenue, remaining performance obligations               $ 5,000,000.0
Grifols | Research Services                
Collaborations                
Revenue recognized             3,600,000  
Grifols | Licensed Rights                
Collaborations                
Revenue recognized             39,900,000  
Grifols | One-time delivery of drug supply for commercialization                
Collaborations                
Revenue recognized           651,000 651,000  
Grifols | Commercial Milestones                
Collaborations                
Contingent payments       297,500,000        
Grifols | Upon EMA approval of fostamatinib for treatment of chronic ITP                
Collaborations                
Revenue, cumulative catch-up   $ 20,000,000.0            
Kissei                
Collaborations                
Upfront payment received         $ 33,000,000.0      
Contingent payments         $ 147,000,000.0      
Revenue recognized           0 0  
Revenue, remaining performance obligations           33,000,000.0 33,000,000.0  
Daiichi | Collaborative arrangement                
Collaborations                
Revenue recognized           2,100,000 2,100,000  
fostamatinib | Grifols                
Collaborations                
Collaborative payment received $ 20,000,000.0              
fostamatinib | Grifols | Upon EMA approval of fostamatinib for treatment of chronic ITP                
Collaborations                
Contingent payments       $ 20,000,000.0        
Collaborative payment received 17,500,000              
fostamatinib | Grifols | Creditable advance royalty payment                
Collaborations                
Collaborative payment received $ 2,500,000              
fostamatinib | Grifols | Maximum                
Collaborations                
Royalty payment as a percentage of net sales       30.00%        
fostamatinib | Kissei                
Collaborations                
Revenue, remaining performance obligations           $ 1,400,000 $ 1,400,000  
fostamatinib | Medison Pharma | Financing arrangement                
Collaborations                
Upfront payment received     $ 5,000,000.0          
fostamatinib | Medison Pharma | Commercial and license agreements                
Collaborations                
Number of agreements | agreement     2